SUMMIT, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Celgene Corporation reviewed recent corporate highlights and provided its outlook for 2007 milestones at the JPMorgan 25th Annual Healthcare Conference. In 2006, Celgene achieved exceptional results in its commercial, financial, clinical, regulatory and international performance, underscored by FDA approvals for REVLIMID(R) and THALOMID(R), and three product launches that delivered record results towards maximizing the commercial potential of REVLIMID and THALOMID for the treatment of patients with certain blood cancers in the U.S.
The Company’s commercial performance was based on record total revenue and profits supported primarily by multiple product revenue streams including, REVLIMID, THALOMID, ALKERAN(R), FOCALIN XR(TM) and the Ritalin Family of products. The successful growth of product revenue continues to reflect the positive reception by hematologist/oncologists for REVLIMID and THALOMID based on the approved indications, clinical findings presented worldwide at major international medical meetings, and clinical data reported in peer-reviewed publications.
In 2006, preliminary unaudited results indicate that total revenue will increase by 60 percent, year-over-year, to approximately $890 million. Adjusted diluted earnings per share nearly tripled. The Company will report its 2006 full-year financial results on February 1, 2007.
2007 total revenue growth is targeted to increase to a $1.3 billion range, and adjusted diluted earnings per share are targeted to double to approximately $1.00.
Webcast
A Webcast of the Company’s JPMorgan 25th Annual Healthcare Conference presentation, scheduled for Monday, January 8 at 4:30 pm PT, can be accessed by going to Celgene’s website, www.celgene.com, and clicking on “Investor Relations,” and then “webcast event.” This event will be archived and accessible until 12:00 p.m. ET, January 15, 2007 at Celgene’s Investor Relations page.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company’s website at www.celgene.com.
This release contains forward-looking statements which are subject to known and unknown risks, delays, uncertainties and other factors not under the Company’s control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and other factors described in the Company’s filings with the Securities and Exchange Commission such as our 10K, 10Q and 8K reports.
Celgene Corporation
CONTACT: Robert J. Hugin, President and Chief Operating Officer,+1-908-673-9102, or Brian P. Gill, Vice President, CorporateCommunications, +1-908-673-9530, both of Celgene Corporation
Web site: http://www.celgene.com/
